

UCSF

UC San Francisco Previously Published Works

Title

Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS

Permalink

<https://escholarship.org/uc/item/0hz0w939>

Journal

Neurobiology of Aging, 34(9)

ISSN

0197-4580

Authors

Ravenscroft, Thomas A
Baker, Matt C
Rutherford, Nicola J
[et al.](#)

Publication Date

2013-09-01

DOI

10.1016/j.neurobiolaging.2013.04.004

Peer reviewed

Published in final edited form as:

Neurobiol Aging. 2013 September ; 34(9): 2235.e11–2235.e13. doi:10.1016/j.neurobiolaging.2013.04.004.

Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS

Thomas A. Ravenscroft^a, Matt C. Baker^a, Nicola J. Rutherford^a, Manuela Neumann^{b,c}, Ian R. Mackenzie^d, Keith A. Josephs^e, Bradley F. Boeve^e, Ronald Petersen^e, Glenda M. Halliday^f, Jillian Kriil^g, John C. van Swieten^h, William W. Seeleyⁱ, Dennis W. Dickson^a, and Rosa Rademakers^{a,*}

^aDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA

^bDepartment of Neuropathology, University of Tübingen, Tübingen, Germany

^cGerman Center for Neurodegenerative Diseases, Tübingen, Germany

^dDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada

^eDepartment of Neurology, Mayo Clinic, Rochester, MN, USA

^fNeuroscience Research Australia, Sydney, NSW, and UNSW Medicine, University of New South Wales, Sydney, NSW, Australia

^gDisciplines of Medicine and Pathology, Sydney Medical School, The University of Sydney, NSW, Australia

^hDepartment of Neurology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, and Vumc Alzheimercenter, Amsterdam

ⁱDepartment of Neurology, University of California, San Francisco, CA, USA

Abstract

The nuclear protein fused in sarcoma (FUS) is found in cytoplasmic inclusions in a subset of patients with the neurodegenerative disorder frontotemporal lobar degeneration (FTLD-FUS). FUS contains a methylated arginine-glycine-glycine domain which is required for transport into the nucleus. Recent findings have shown that this domain is hypomethylated in patients with FTLD-FUS. To determine if the cause of hypomethylation is the result of mutations in protein N-arginine methyltransferases (PRMTs), we selected 3 candidate genes (*PRMT1*, *PRMT3* and *PRMT8*) and performed complete sequencing analysis and real-time PCR mRNA expression analysis in 20 FTLD-FUS cases. No mutations or statistically significant changes in expression were observed in our patient samples, suggesting that defects in PRMTs are not the cause of FTLD-FUS.

© 2013 Elsevier Inc. All rights reserved.

*Corresponding author: Rosa Rademakers, Ph.D., Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL 32224, Phone: (904) 953-6279, Fax: (904) 953-7370, Rademakers.rosa@mayo.edu.

Disclosure Statement

The authors disclose no conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. Introduction

Frontotemporal Dementia (FTD) refers to a group of clinical syndromes characterized by progressive changes in behaviour and personality or language. A subgroup of these patients are pathologically characterized by fused in sarcoma (FUS)-positive and TAR DNA binding protein 43 (TDP-43)-negative cytoplasmic inclusions in neuronal and glial cells and referred to as FTLD-FUS (Josephs, et al., 2008, Mackenzie, et al., 2010, Neumann, et al., 2009, Rohrer, et al., 2009, Rohrer, et al., 2011, Seelaar, et al., 2010). Although mutations in *FUS* are known to cause around 4% of familial amyotrophic lateral sclerosis (ALS) (Kwiatkowski, et al., 2009, Vance, et al., 2009); any genetic causes of FTLD-FUS remain unknown (Snowden, et al., 2011, Urwin, et al., 2010).

FUS belongs to the FET family of proteins along with Ewing's sarcoma protein (EWS), and the TATA-binding protein-associated factor 15 (TAF15) both of which coaggregate in inclusions with FUS in FTLD-FUS cases (Mackenzie and Neumann, 2012, Neumann, et al., 2011). In addition to FET proteins the cytoplasmic inclusions in FTLD-FUS also contain the nuclear import protein Transportin (TRN) (Neumann, et al., 2012). TRN binds to the shared proline-tyrosine rich C-terminal nuclear localisation signal (PY-NLS) of the FET proteins and transports them between the nucleus and cytoplasm (Chook and Suel, 2011). FET proteins contain an extensively methylated RGG domain (Arginine-Glycine-Glycine) and there is strong evidence to show that dimethylation of the arginine residues in this domain can disrupt the nuclear localisation of the FET proteins (Jobert, et al., 2009, Tradewell, et al., 2012). Moreover, recent findings show a novel TRN binding motif in the RGG domain of FET proteins and the hypomethylation of arginine in this region increases the binding capacity of TRN to FET proteins, the consequence of which is mislocalisation (Dormann, et al., 2012). Since type I Protein N-arginine methyltransferases (PRMTs) dimethylate arginine residues *in vivo*, we hypothesised that mutations in the genes encoding *PRMT1*, *PRMT3* and *PRMT8*, all previously shown to methylate FET proteins *in vitro* (Kim, et al., 2008, Pahlich, et al., 2005), could contribute to the hypomethylation observed in FTLD-FUS.

2. Subjects, Materials and Methods

Through an international collaboration, we collected samples from 20 FTLD-FUS patients from the United States, Canada, Germany, the Netherlands and Australia (Sup. Table 1). All patients had the atypical FTLD-U subtype of FTLD-FUS. DNA of all 20 patients was sequenced for all coding exons and both 3' and 5' untranslated regions of *PRMT1*, *PRMT3* and *PRMT8*. DNA fragments were amplified using Apex products, purified using the Agencourt Ampure system and sequenced using Big Dye Terminator V3.1 products. Sequencing purification was performed using the Agencourt CleanSEQ method, run on an ABI3730 DNA-analyser with Sequencher used for analysis.

For quantitative real-time PCR mRNA analysis a subset of 8 patients with FTLD-FUS and 7 control brains was used to quantify RNA levels in frontal cortex. RNA was prepared using a Qiagen RNeasyplus mini kit, and cDNA was made using Invitrogen Superscript III first-strand kit. Samples used for the study are indicated in Sup. Table 1. Expression levels of *PRMT1* (Hs01587651), *PRMT3* (Hs00411605) and *PRMT8* (Hs00998598) as well as the housekeeping gene RPLP0 (Hs00420895) and the neuronal marker Synaptophysin (Hs00300531) were measured on an Applied Biosystems 7900HT fast real-time PCR system and analysed using relative quantification ($\Delta\Delta$ Ct) in SDS 2.2.2.

3. Results

Sequencing analysis of *PRMT1*, *PRMT3* and *PRMT8* in FTLD-FUS patients did not reveal any novel sequence variants. In *PRMT3* and *PRMT8* we did identify a number of known

sequence variants (Sup. Table 2). Quantitative mRNA expression analysis of *PRMT1* and *PRMT3* in frontal cortex brain samples did not show a significant difference in expression between the FTLD-FUS cases and controls (P values of 0.523 and 0.2602 respectively). In contrast, we found that expression levels of *PRMT8* were significantly lower in the frontal cortex of subjects with FTLD-FUS in comparison to controls (P=0.0231) (Sup. Fig. 1). However, when the neuronal marker synaptophysin was used for normalization no statistical difference was observed between FTLD-FUS patients and control brains (P=0.3842), suggesting that the decrease in *PRMT8* expression was due to the neuronal specificity of *PRMT8* (Sup. Fig. 2).

4. Discussion

While mutations in *FUS* explain the disease in all ALS patients with FUS pathology, the cause of FUS pathology in patients with FTLD remains unknown (Snowden, et al., 2011, Urwin, et al., 2010). Importantly, recent studies highlight important differences between ALS-FUS and FTLD-FUS suggesting distinct pathomechanisms. First, in contrast to ALS-FUS, pathological inclusions in FTLD-FUS cases contain EWS and TAF15, as well as TRN, suggesting a more general defect in TRN-mediated nuclear import in FTLD-FUS (Mackenzie and Neumann, 2012, Neumann, et al., 2011, Neumann, et al., 2012). Second, the inclusions in ALS-FUS patients contain methylated FUS, while inclusions in FTLD-FUS patients are not methylated (Dormann, et al., 2012, Tradewell, et al., 2012).

Based on these findings, we hypothesized that the hypomethylation of FUS seen in FTLD-FUS patients was a consequence of mutations in or the altered expression of the N-arginine methylation proteins PRMT1, PRMT3 or PRMT8. However, in-depth sequencing of all coding, as well as 5' and 3' untranslated regions, and quantitative real-time mRNA expression analysis did not identify any mutations or differences in expression between FTLD-FUS patients and controls. These results indicate that the mislocalisation of FUS proteins in FTLD-FUS is not a consequence of any genetic variants in *PRMT1*, *PRMT3* or *PRMT8*.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work is funded by a Mayo Benefactor and the Mayo Foundation. This work is further supported by the National Institute of Health grant number P50 AG016574, R01 NS065782, R01 AG026251, R01 AG037491, P50 AG023501, The Consortium for Frontotemporal Dementia Research and the Swiss National Science Foundation (31003A-132864). IM is supported by the Canadian Institutes of Health Research (grant # 74580) and the Pacific Alzheimer's Research Foundation (C06-01). Tissues from Australia were received from the Sydney Brain Bank which is supported by the National Health and Medical Research Council of Australia, The University of New South Wales, and Neuroscience Research Australia.

References

- Chook YM, Suel KE. Nuclear import by karyopherin-beta s: Recognition and inhibition. *Biochimica Et Biophysica Acta-Molecular Cell Research*. 2011; 1813(9):1593–606.10.1016/j.bbamcr.2010.10.014
- Dormann D, Madl T, Valori CF, Bentmann E, Tahirovic S, Abou-Ajram C, Kremmer E, Ansorge O, Mackenzie IRA, Neumann M, Haass C. Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. *Embo Journal*. 2012; 31(22):4258–75.10.1038/emboj.2012.261 [PubMed: 22968170]

- Jobert L, Argentini M, Tora L. PRMT1 mediated methylation of TAF15 is required for its positive gene regulatory function. *Experimental Cell Research*. 2009; 315(7):1273–86.10.1016/j.yexcr.2008.12.008 [PubMed: 19124016]
- Kim JD, Kako K, Kakiuchi M, Park GG, Fukamizu A. EWS is a substrate of type I protein arginine methyltransferase, PRMT8. *International Journal of Molecular Medicine*. 2008; 22(3):309–15.10.3892/ijmm_00000024 [PubMed: 18698489]
- Kwiatkowski TJ, Bosco DA, LeClerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Ticozzi N, Siddique T, McKenna-Yasek D, Sapp PC, Horvitz HR, Landers JE, Brown RH. Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis. *Science*. 2009; 323(5918):1205–8.10.1126/science.1166066 [PubMed: 19251627]
- Mackenzie IRA, Neumann M. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis. *Brain Research*. 2012; 1462:40–3.10.1016/j.brainres.2011.12.010 [PubMed: 22261247]
- Neumann M, Bentmann E, Dormann D, Jawaid A, DeJesus-Hernandez M, Ansorge O, Roeber S, Kretzschmar HA, Munoz DG, Kusaka H, Yokota O, Ang LC, Bilbao J, Rademakers R, Haass C, Mackenzie IRA. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. *Brain*. 2011; 134:2595–609.10.1093/brain/awr201 [PubMed: 21856723]
- Neumann M, Valori CF, Ansorge O, Kretzschmar HA, Munoz DG, Kusaka H, Yokota O, Ishihara K, Ang LC, Bilbao JM, Mackenzie IRA. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations. *Acta Neuropathologica*. 2012; 124(5):705–16.10.1007/s00401-012-1020-6 [PubMed: 22842875]
- Pahlich S, Bschor K, Chiavi C, Belyanskaya L, Gehring H. Different methylation characteristics of protein arginine methyltransferase 1 and 3 toward the Ewing sarcoma protein and a peptide. *Proteins-Structure Function and Bioinformatics*. 2005; 61(1):164–75.10.1002/prot.20579
- Snowden JS, Hu Q, Rollinson S, Halliwell N, Robinson A, Davidson YS, Momeni P, Baborie A, Griffiths TD, Jaros E, Perry RH, Richardson A, Pickering-Brown SM, Neary D, Mann DMA. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. *Acta Neuropathologica*. 2011; 122(1):99–110.10.1007/s00401-011-0816-0 [PubMed: 21424531]
- Tradewell ML, Yu ZB, Tibshirani M, Boulanger MC, Durham HD, Richard S. Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. *Human Molecular Genetics*. 2012; 21(1):136–49.10.1093/hmg/ddr448 [PubMed: 21965298]
- Urwin H, Josephs KA, Rohrer JD, Mackenzie IR, Neumann M, Authier A, Seelaar H, Van Swieten JC, Brown JM, Johannsen P, Nielsen JE, Holm IE, Dickson DW, Rademakers R, Graff-Radford NR, Parisi JE, Petersen RC, Hatanpaa KJ, White CL, Weiner MF, Geser F, Van Deerlin VM, Trojanowski JQ, Miller BL, Seeley WW, van der Zee J, Kumar-Singh S, Engelborghs S, De Deyn PP, Van Broeckhoven C, Bigio EH, Deng HX, Halliday GM, Kriil JJ, Munoz DG, Mann DM, Pickering-Brown SM, Doodeman V, Adamson G, Ghazi-Noori S, Fisher EMC, Holton JL, Revesz T, Rossor MN, Collinge J, Mead S, Isaacs AM, Consortium FR. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. *Acta Neuropathologica*. 2010; 120(1):33–41.10.1007/s00401-010-0698-6 [PubMed: 20490813]
- Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Ganesalingam J, Williams KL, Tripathi V, Al-Saraj S, Al-Chalabi A, Leigh PN, Blair IP, Nicholson G, de Belleruche J, Gallo JM, Miller CC, Shaw CE. Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6. *Science*. 2009; 323(5918):1208–11.10.1126/science.1165942 [PubMed: 19251628]